Cadila Healthcare launches influenza vaccine

Cadila Healthcare has received regulatory approvals to launch tetravalent inactivated influenza vaccine for seasonal flu in India.

The  pharmaceutical company has got nod from Drug Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO) and Central Drug Laboratory (CDL) to market the tetravalent inactivated influenza vaccine Vaxiflu 4 for seasonal flu. The vaccine has been developed at the company's vaccine technology centre in Ahmedabad. It provides protection from four influenza viruses like H1N1, H3N2, Type B (Brisbane) and Type B (Phuket).

With the launch of vaccines like Vaxiflu 4, Cadila Healthcare aims to serve the cause of public health and meeting the twin challenge of affordability and accessibility. CDSCO is the central drug authority for discharging functions assigned to the Central government under the Drugs and Cosmetics Act. Its mandate is to safeguard and enhance public health by assuring the safety, efficacy and quality of drugs, cosmetics and medical devices.

The share price of Cadila Healthcare decreased 1.04 per cent and closed at Rs 430.05 on Thursday. On Monday, there may be positive opening for the stock.